2010

40 publications

  • Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).
    Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    N Engl J Med. 2010 Dec 23;363(26):2511-21.
  • Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, Grarup N, Sparso T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proenca C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O’Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YD, Chines P, Clarke R, Coin LJ, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day IN, de Geus EJ, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PR, Jorgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martinez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R, Palmer CN, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AF, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, Sigurethsson G, Sijbrands EJ, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvanen AC, Tanaka T, Thorand B, Tichet J, Tonjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JC, Yarnell JW, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, Borecki IB, Loos RJ, Meneton P, Magnusson PK, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WH, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP.
    New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.
    Nat Genet 2010; 42(2):105-116.
  • Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segre AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Bengtsson BK, Bravenboer B, Bumpstead S, Burtt NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, Doney AS, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PR, Jorgensen T, Kao WH, Klopp N, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JR, Petersen AK, Platou C, Proenca C, Prokopenko I, Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparso T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van Haeften TW, van Herpt T, Vliet-Ostaptchouk JV, Bragi WG, Weedon MN, Wijmenga C, Witteman J, Bergman RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso M, Mohlke KL, Morris AD, Palmer CN, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann HE, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, McCarthy MI.
    Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis.
    at Genet 2010; 42(7):579-589.
  • Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Rudolltz M, Jin Y, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes E, Guilhot F, on behalf of the TOPS investigators ;
    Response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase: 24 month update from TOPS (tyrosine kinase inhibitor optimization and selectivity) study,
    J Clin Onc 2010 sous presse
  • Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques.
    Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained a complete molecular response for at least 2 years: the multicentre Stop Imatinib (STIM) trial.
    Lancet Oncol. 2010 Nov;11(11):1029-35.
  • Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, Yip C, Holyoake T, Jorgensen H, Lambie K, Saw KM, Pang E, Vukovic R, Lehn P, Ringrose A, Yu M, Brinkman RR, Smith C, Eaves A, Eaves C.
    Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
    Blood 2010 Sep 23;116(12):2112-21.
  • Le Jeune F, Vérin M, N’Diaye K, Drapier D, Leray E, Du Montcel ST, Baup N, Pelissolo A, Polosan M, Mallet L, Yelnik J, Devaux B, Fontaine D, Chereau I, Bourguignon A, Peron J, Sauleau P, Raoul S, Garin E, Krebs MO, Jaafari N, Millet B; French Stimulation dans le trouble obsessionnel compulsif (STOC) study group.
    Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study.
    Biol Psychiatry. 2010 Dec 1;68(11):1016-22.
  • Abi KC, Travert F, Fetita S, Rouzet F, Porcher R, Riveline JP, Hadjadj S, Larger E, Roussel R, Vexiau P, Le Guludec D, Gautier JF, Marre M.
    Fetal exposure to maternal type 1 diabetes is associated with renal dysfunction at adult age.
    Diabetes 2010 Oct;59(10):2631-6.
  • Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L, Bonnetain F.
    Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.
    J Hepatol. 2011 Jan;54(1):108-14.
  • Hankard R.
    Research training and residents.
    CMAJ 2010 ; 182: 10. 1080-1081.
  • Vogt L, Chiurchiu C, Chadha-Boreham H, Danaietash P, Dingemanse J, Hadjadj S, Krum H, Navis G, Neuhart E, Parvanova AI, Ruggenenti P, Woittiez AJ, Zimlichman R, Remuzzi G, de Zeeuw D.
    Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy.
    Hypertension 2010; 55(5):1206-1209.
  • Alkhalaf A, Bakker SJ, Bilo HJ, Gans RO, Navis GJ, Postmus D, Forsblom C, Groop PH, Vionnet N, Hadjadj S, Marre M, Parving HH, Rossing P, Tarnow L.
    A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus.
    Diabetologia 2010 Dec;53(12):2562-8.
  • Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JE.
    Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
    Haematologica 2010; 95(8):1325-1333.
  • Regnault N, Botton J, Forhan A, Hankard R, Thiebaugeorges O, Hillier TA, Kaminski M, Heude B, Charles MA.
    Determinants of early ponderal and statural growth in full-term infants in the EDEN mother-child cohort study.
    Am J Clin Nutr . 2010 Sep;92(3):594-602.
  • Couturier J, Morel M, Pontcharraud R, Gontier V, Fauconneau B, Paccalin M, Page G.
    Interaction of double-stranded RNA-dependent protein kinase (PKR) with the death receptor signaling pathway in amyloid beta (Abeta)-treated cells and in APPSLPS1 knock-in mice.
    J Biol Chem. 2010 Jan 8;285(2):1272-82.
  • Maimaitiming S, Roussel R, Hadjadj S, Fumeron F, Aubert R, Emery N, Velho G, Mohammedi K, Travert F, Tichet J, Alhenc-Gelas F, Balkau B, Marre M.
    Association of common variants in NPPA and NPPB with blood pressure does not translate into kidney damage in a general population study.
    J Hypertens 2010; 28(6):1230-1233.
  • Worbe Y, Mallet L , Golmard JL, Durif F, Jalenques I, Damier P, Derkinderen P, Pollak P, Anheim M, Broussolle E, Xie J, Mondon K , Jedynak FP, Djebara B, Pelissolo A , Vidailhet M, Agid Y , Houeto JL and Hartmann A.
    Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both?
    PLoSONE, 2010 Sep 24;5(9):e12959.
  • Bouche G, Ingrand I, Mathoulin-Pelissier S, Ingrand P, Breton-Callu C, Migeot V.
    Determinants of variability in waiting times for radiotherapy in the treatment of breast cancer.
    Radiother. Oncol. 2010 Dec;97(3):541-7.
  • Couturier J, Page G, Morel M, Gontier C, Lecron JC, Pontcharraud R, Fauconneau B, Paccalin M.
    Inhibition of Double-Stranded RNA-Dependent Protein Kinase Strongly Decreases Cytokine Production and Release in Peripheral Blood Mononuclear Cells from Patients with Alzheimer’s Disease.
    J Alzheimers Dis. 2010;21(4):1217-31.
  • Debouverie O, Coudroy R, Merlet-Chicoine I, Salmon F, Paccalin M.
    Accuracy of fluoropropyl-2B-carbomethoxy-3B(4-iodophenyl) nortrpane datscan for the diagnosis of lewy body dementia.
    J Am Geriatr Soc. 2010 Jan;58(1):209-10.
  • Sorel N, Mayeur-Rousse C, Deverrière S, Roy L, Brottier-Mancini E, Guilhot F, Turhan AG, Chomel JC.

    Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.
    J Mol Diagn. 2010;12(4):520-4.

  • Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, Miot A, Saulnier PJ, Travert F, Hadjadj S, Marre M, Fumeron F.
    Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes.
    Nephrol Dial Transplant 2010;25(7):2231-7.
  • Mok E, Letellier G, Cuisset JM, Denjean A, Gottrand f, Hankard R:
    Assessing change in body composition in children with Duchenne muscular dystrophy: Anthropometry and bioelectrical impedance analysis versus dual-energy X-ray absorptiometry.
    Clin Nutr 2010 Oct;29(5):633-8.
  • Filozof C, Gautier JF.
    A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Diabet Med 2010; 27(3):318-326.(S Hadjadj CIC0802 en remerciements)
  • Regnault N, Botton J, Blanc L, Hankard R, Forhan A, Goua V, Thiebaugeorges O, Kaminski M, Heude B, Charles MA;
    EDEN mother-child cohort study group. Determinants of neonatal weight loss in term-infants: specific association with pre-pregnancy maternal body mass index and infant feeding mode.
    Arch Dis Child Fetal Neonatal Ed. 2011 May;96(3):F217-22.
  • Mcheik JN, Dichamp I, Levard G, Ragot S, Beby-Defaux A, Grosos C, Couvrat V, Agius G.
    Infantile hypertrophic pyloric stenosis: are viruses involved?
    J Med Virol. 2010 Dec;82(12):2087-91.
  • Hadjadj S, Gourdy P,Gallois Y, Leroux S, Halimi JM, Dardari D, Guilloteau G, Saulnier PJ , Roussel R , Dupuis O, Verrier-Mine O, Lecomte P :
    Serum estradiol was associated with diabetic nephropathy.
    Diabetes Metab. 2010 36: Iss. 1; A28-A28
  • Taouqi M, Ingrand I, Beauchant M, Migeot V, Ingrand P.
    Determinants of participation in colonoscopic screening by siblings of colorectal cancer patients in France.
    BMC Cancer. 2010; 6;10:355
  • De Luca A, Boisseau N, Tea I., Robins RJ, Charles MA, Hankard R
    Estimation of protein intake in human being by measuring 15N and 13C hair content Fundam.
    Clin. Pharmacol. 2010; 24; 104-104 Suppl. 1
  • Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe Francophone des Myélodysplasies).
    Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res. 2010;34(7):864-70.
  • Joha S, Dauphin V, Lepretre F, Corm S, Nicolini FE, Roumier C, Nibourel O, Grardel N, Maguer-Satta V, Idziorek T, Figeac M, Lai JL, Quesnel B, Etienne G, Guilhot F, Lippert E, Preudhomme C, Roche-Lestienne C.
    Genomic characterization of Imatinib resistance in CD34(+) cell populations from chronic myeloid leukaemia patients.
    Leuk Res 2011 Apr;35(4):448-58.
  • Joha S, Dauphin V, Lepretre F, Corm S, Nicolini FE, Roumier C, Nibourel O, Grardel N, Maguer-Satta V, Idziorek T, Figeac M, Lai JL, Quesnel B, Etienne G, Guilhot F, Lippert E, Preudhomme C, Roche-Lestienne C.
    Genomic characterization of Imatinib resistance in CD34(+) cell populations from chronic myeloid leukaemia patients.
    Leuk Res 2011. 35(4):448-58.
  • Fargeau MN, Jaafari N, Ragot S, Houeto JL, Pluchon C, Gil R.
    Alzheimer’s disease and impairment of the Self.
    Conscious Cogn 2010 Dec;19(4):969-76.
  • Robert R, Guilhot J, Pinsard M, Longeard PL, Jacob JP, Gissot V, Hauet T, Seguin F.
    A pair analysis of the delayed graft function in kidney recipient: The critical role of the donor.
    J Crit Care. 2010 Dec;25(4):582-90.
  • B. Filloux, C Chagneau-Derrode, S Ragot, J Voultoury, M Morichaud-Beauchant, C Silvain, R Robert.
    Short-term and long-term vital outcome of cirrhotic patients admitted to an intensive care unit.
    Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1474-80.
  • Binder P, Caron C, Jouhet V, Marcelli D, Ingrand P.
    Adolescents consulting a GP accompanied by a third party: comparative analysis of representations and how they evolve through consultation.
    Fam Pract 2010 Oct;27(5):556-62.
  • Epstein S, Geniteau E, Christin P, Hermouet P, Mok E, Fournier J, Hankard R.
    Role of a clinical nurse specialist within a paediatric multidisciplinary weight-management programme team.
    J Clin Nurs. 2010 Sep;19(17-18):2649-51. doi: 10.1111/j.1365-2702.2010.03296.x.
  • Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, Nicolas-Virelizier E, Michallet M, Tigaud I, Magaud JP, Turhan A, Guilhot F, Hayette S.
    The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
    Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):394-9.
  • Paillot C, Ingrand P, Millet B, Amador XF, Senon JL, Olié JP, Jaafari N; Insight Study Group.
    Traduction et validation française de l’échelle d’évaluation de la conscience des troubles mentaux des patients schizophrènes : The Scale to assess Unawareness of Mental Disorder (SUMD).
    Encephale. 2010 Dec;36(6):472-7.
  • Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP.
    Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS).
    Blood. 2010 116(19):3758-65.